Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10521-10531

  Christinat, Yann ^a   Krek, Wilhelm ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Cancer; Clear cell renal cell carcinoma; miRNA; Prognosis; TCGA

Indexed keywords

MICRORNA; MICRORNA 10B; MICRORNA 143; MICRORNA 183; MICRORNA 192; MICRORNA 21; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ARTICLE; BAP1 GENE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER MODEL; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; OVERALL SURVIVAL; TUMOR SUPPRESSOR GENE; CLASSIFICATION; COHORT ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; KIDNEY TUMOR; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS;

CARCINOMA, RENAL CELL; COHORT STUDIES; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84929591063     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3294     Document Type: Article

References (37)

1. American Cancer Society: Cancer Facts & Figures 2012. Atlanta Am Cancer Soc. 2012.
2. Zhang L, Xu B, Chen S, Lu K, Liu C, Wang Y, Zhao Y, Zhang X, Liu D, Chen M. The complex roles of microRNAs in the metastasis of renal cell carcinoma. J. Nanosci. Nanotechnol. 2013; 13:3195-3203.
3. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, Gulati S, Bates PA, Stamp G, Pickering L, Gore M, Nicol DL, Hazell S, Futreal PA, Stewart A, Swanton C. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 2014/02/04 ed. Nature Publishing Group; 2014; 46:1-12.
4. Linehan WM, Rathmell WK. Kidney cancer. Urol. Oncol. Elsevier Inc.; 2012; 30:948-951.
5. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 2010; 17:1471-1474.
6. Schoof C, Botelho E da S. MicroRNAs in cancer treatment and prognosis. Am J Cancer Res. 2012; 2:414-433.
7. Chen J, Zhang D, Zhang W. Clear cell renal cell carcinoma associated microRNA expression signatures identified by an integrated bioinformatics analysis. J. Transl. Med. Journal of Translational Medicine. 2013; 11:1-11.
8. Heinzelmann J, Henning B. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J. Urol. 2011; 29:367-373.
9. Slaby O, Redova M. Identification of microRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes. Chromosomes Cancer. 2012; 51:707-716.
10. Wotschofsky Z, Busch J, Jung M. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin. Chim. Acta. 2012; 416:5-10.
11. Wu X, Weng L, Li X, Guo C, Pal S, Jin J. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One. 2012; 7:1-10.
12. Fritz HKM, Lindgren D, Ljungberg B, Axelson H, Dahlbäck B. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer. 2014; 50:1758-1765.
13. Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG, Cairns P. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol. Ther. 2014; 15:329-341.
14. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ. Teh BINT. MicroRNA profiling of human kidney cancer subtypes. 2009; 109-114.
15. Binder H, Porzelius C, Schumacher M. An overview of techniques for linking high-dimensional molecular data to time-to-event endpoints by risk prediction models. Biometrical J. 2011; 53:170-189.
16. The Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 24:3-9.
17. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, Chen CC, Song SW, Jiang T. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in chinese patients with primary glioblastoma multiforme. Cancer. 2013; 119:814-824.
18. Han Z, Zhong L, Teng M, Fan J, Tang H. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol. Oncol. Elsevier B.V. 2012; 6:445-457.
19. Shih KK, Qin L-X, Tanner EJ, Zhou Q, Bisogna M, Dao F, Olvera N, Viale A, Barakat RR, Levine D a. A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol. Oncol. Elsevier Inc. 2011; 121:444-450.
20. Harrell F, Lee K, Mark D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15:361-387.
21. Kattan MW. Validating a prognostic model. Cancer. 2006; 107:2523-2524.
22. Margolin Aa, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HKM, Rueda OM, Guinney J, Deflaux Na, Hoff B, Schildwachter X, Russnes HG, Park D, Vang VO, Pirtle T, Youseff L, Citro C, Curtis C, Kristensen VN, Hellerstein J, Friend SH, Stolovitzky G, Aparicio S, Caldas C, Børresen-Dale A-L. Systematic analysis of challenge- driven improvements in molecular prognostic models for breast cancer. Sci. Transl. Med. 2013; 5:181re1.
23. Khella HWZ, Bakhet M, Allo G, Jewett M a S, Girgis a H, Latif a, Girgis H, Von Both I, Bjarnason G a, Yousef GM. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis. 2013; 34:2231-2239.
24. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed. Inform. Elsevier Inc. 2011; 44:839-847.
25. Peitsch WK, Grund C, Kuhn C, Schnölzer M, Spring H, Schmelz M, Franke WW. Drebrin is a widespread actinassociating protein enriched at junctional plaques, defining a specific microfilament anchorage system in polar epithelial cells. Eur J Cell Biol. 1999; 78:767-778.
26. Häbig K, Gellhaar S, Heim B, Djuric V, Giesert F, Wurst W, Walter C, Hentrich T, Riess O, Bonin M. LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and Tropomyosin 4. Biochim. Biophys. Acta Elsevier B.V. 2013; 1832:2352-2367.
27. Hong J-P, Li X-M, Li M-X, Zheng F-L. VEGF suppresses epithelial-mesenchymal transition by inhibiting the expression of Smad3 and miR-192, a Smad3-dependent microRNA. Int J. Mol. Med. 2013; 31:1436-1442.
28. Zigeuner R, Hutterer G, Chromecki T, Imamovic A, Kampel-Kettner K, Rehak P, Langner C, Pummer K. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur. Urol. 2010; 57:102-109.
29. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol. European Association of Urology. 2014; :1-8.
30. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 2013.
31. Brugarolas J. PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J. 2013; 19:324-332.
32. Kruetzfeldt J, Roesch N, Hausser J, Manoharan M, Zavolan M, Stoffel M. MicroRNA-194 Is a Target of Transcription Factor 1 (Tcf1, HNF1 a ) in Adult Liver and Controls Expression of Frizzled-6. Hepatology. 2012; 55:98-107.
33. Deshpande SD, Putta S, Wang M, Lai JY, Bitzer M, Nelson RG, Lanting LL, Kato M, Natarajan R. Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes. 2013; 62:3151-3162.
34. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl. Cancer Inst. 2005; 97:1180-1184.
35. Nissan T, Parker R. Computational analysis of miRNAmediated repression of translation: implications for models of translation initiation inhibition. RNA. 2008; 14:1480-1491.
36. Dillies M-A, Rau A, Aubert J, Hennequet-Antier C, Jeanmougin M, Servant N, Keime C, Marot G, Castel D, Estelle J, Guernec G, Jagla B, Jouneau L, Laloë D, Le Gall C, Schaëffer B, Le Crom S, Guedj M, Jaffrézic F. A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis. Brief. Bioinform. 2012; 14:671-683.
37. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010; 11:367.